Titan Pharmaceuticals, Inc.
TTNP
$5.09
-$0.21-3.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.67% | -63.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.67% | -63.65% | |||
| Operating Income | 11.67% | 63.65% | |||
| Income Before Tax | -3.54% | 63.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.54% | 63.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.54% | 63.55% | |||
| EBIT | 11.67% | 63.65% | |||
| EBITDA | 11.67% | 63.59% | |||
| EPS Basic | -3.53% | 63.54% | |||
| Normalized Basic EPS | -3.55% | 63.55% | |||
| EPS Diluted | -3.53% | 63.54% | |||
| Normalized Diluted EPS | -3.55% | 63.55% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||